POST Online Media Lite Edition


Pfizer appoints Albert Bourla as COO

Staff Writer |
New York, N.Y., USA - Pfizer, a biopharmaceutical company, announced that Albert Bourla has been named chief operating officer effective January 1, 2018.

Article continues below

Dr. Bourla has been the Group President of Pfizer’s Innovative Health Business since the beginning of 2016.

Prior to his current position Dr. Bourla was the Group President for Pfizer’s Vaccines, Oncology and Consumer Healthcare businesses where he was instrumental in building a strong and competitive position in Oncology and expanded the company’s leadership in vaccines.

Over the course of his career he has held a number of senior global positions across a range of businesses and geographies.

Prior to leading the Established Products business, Dr. Bourla was the Area President for Pfizer’s Animal Health business across Europe, Africa, and Asia Pacific where he successfully managed the integration of Wyeth’s Animal Health Business (Fort Dodge) with Pfizer in these global markets.

Dr. Bourla has significant scientific expertise.


What to read next

Pfizer appoints James C. Smith as director
Pfizer: Olivier Brandicourt president and GM, Emerging Markets and Established Products
Pfizer elects George A. Lorch non-executive chairman